Literature DB >> 8306036

Adenosine-induced bronchoconstriction in conscious hyperresponsive and sensitized guinea pigs.

J R Thorne1, K J Broadley.   

Abstract

Inhaled adenosine induces bronchoconstriction in asthmatic and allergic subjects but not in nonasthmatics. This study examined the responses of conscious guinea pigs in which antigen sensitization is induced by ovalbumin pretreatment and airway hyperresponsiveness to carbachol is induced by exposure to ozone and platelet-activating factor-acether (PAF). Airway responses to aerosol challenge with carbachol or adenosine were determined as the change in specific airway conductance (SGaw) measured by whole-body plethysmography. In untreated animals, carbachol (20 micrograms/ml, 60 s) induced a rapid fall in SGaw (peak, 18 +/- 5% at 5 min) indicative of bronchoconstriction, whereas adenosine (1 mg/ml, 60 s) caused an increase in SGaw (34 +/- 8% at 15 min). Animals pretreated with ovalbumin displayed similar responses to carbachol (14 +/- 5% at 5 min) as control animals and were therefore sensitized but not hyperresponsive. However, adenosine (1 mg/ml) caused a rapid bronchoconstriction, peaking at 20 min (25 +/- 5%). Exposure of animals to nebulized PAF-acether (10 micrograms/ml) for 60 s produced a bronchoconstriction, which peaked at 10 min (18 +/- 7%) and returned to basal levels by 60 min. Similarly, exposure to ozone (1.4 ppm) for 60 min caused bronchoconstriction (peak at 20 min, 19 +/- 6%), with recovery after 1 h. Both PAF- and ozone-exposed animals displayed significant hyperresponsiveness to carbachol administered 1 h from the end of the exposure period. The peak bronchoconstrictor responses before and after PAF exposure were 10 +/- 9 and 28 +/- 4%, and responses before and after ozone exposure were 22 +/- 5 and 61 +/- 9%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306036     DOI: 10.1164/ajrccm.149.2.8306036

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  Ozone differentially modulates airway responsiveness in atopic versus nonatopic guinea pigs.

Authors:  Richard B Schlesinger; Mitchell D Cohen; Terry Gordon; Christine Nadziejko; Judith T Zelikoff; Maureen Sisco; Jean F Regal; Margaret G Ménache
Journal:  Inhal Toxicol       Date:  2002-05       Impact factor: 2.724

2.  Evidence for both adenosine A1 and A2A receptors activating single vagal sensory C-fibres in guinea pig lungs.

Authors:  Benjamas Chuaychoo; Min-Goo Lee; Marian Kollarik; Rudolf Pullmann; Bradley J Undem
Journal:  J Physiol       Date:  2006-06-22       Impact factor: 5.182

3.  Mechanism of adenosine-induced airways obstruction in allergic guinea pigs.

Authors:  Sandra Keir; Victoria Boswell-Smith; Domenico Spina; Clive Page
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

4.  Contractile responses to adenosine, R-PIA and ovalbumen in passively sensitized guinea-pig isolated airways.

Authors:  Timothy J Martin; Kenneth J Broadley
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Effects of adenosine on guinea pig pulmonary eosinophils.

Authors:  B A Walker
Journal:  Inflammation       Date:  1996-02       Impact factor: 4.092

6.  Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats.

Authors:  J P Hannon; B Tigani; I Williams; L Mazzoni; J R Fozard
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

7.  Mast cell involvement in the adenosine mediated airway hyper-reactivity in a murine model of ovalbumin-induced lung inflammation.

Authors:  Daniel Wyss; Olivier Bonneau; Alexandre Trifilieff
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

8.  Airway hyper- or hyporeactivity to inhaled spasmogens 24 h after ovalbumin challenge of sensitized guinea-pigs.

Authors:  C A Lewis; K J Broadley
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.